04/06/2026
Multiple myeloma is a rare and often misunderstood blood cancer that affects plasma cells in the bone marrow.
Over the past decade, we have seen meaningful shifts in its treatment landscape. Advances in CAR T-cell therapy, bispecific antibodies, and novel combinations are changing how we think about sequencing, durability of response, and long-term disease management.
At Colorado Blood Cancer Institute, we are actively engaged in clinical research that evaluates emerging therapies across lines of treatment. As an executive member of the Myeloma Research Executive Committee within Sarah Cannon Research Institute, Dr. Peter Forsberg collaborates with investigators nationally to help advance studies that will help define our next generation of care. Learn more about multiple myeloma care at Colorado Blood Cancer Institute: https://bloodcancerinstitute.com/service/blood-cancer